Newcastle University
Toggle Main Menu
Toggle Search
Home
Browse
Latest
Stats
Policies
About
Home
Browse
Latest
Policies
About
ePrints
Browse by author
Browsing publications by
Professor Craig Robson
Newcastle Authors
Title
Year
Full text
Alex Bainbridge
Dr Scott Walker
Joseph Smith
Yi Min Ng Ng
Huw Thomas
et al.
IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway
2020
Dr Anastasia Hepburn
Emma Curry
Dr Mohammad Moad
Laura Wilson
Parmveer Singh
et al.
Propagation of human prostate tissue from induced pluripotent stem cells
2020
Evangelia Kounatidou
Dr Sirintra Nakjang
Dr Stuart McCracken
Professor Craig Robson
Dr Dominic Jones
et al.
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
2019
Professor Craig Robson
Correction: BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration
2019
Dr Anastasia Hepburn
Laura Wilson
Evangelia Kounatidou
Amy Barnard
Philip Berry
et al.
Correction: The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance (Oncogene, (2019), 10.1038/s41388-019-0712-y)
2019
Dr Anastasia Hepburn
Laura Wilson
Evangelia Kounatidou
Amy Barnard
Philip Berry
et al.
The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance
2019
James Grey
Dr Dominic Jones
Laura Wilson
Dr Sirintra Nakjang
Jake Clayton
et al.
Differential regulation of the androgen receptor by protein phosphatase regulatory subunits
2018
Dr Urszula McClurg
Svitlana Korolchuk
Dr Stuart McCracken
Professor Rakesh Heer
Laura Wilson
et al.
Human
ex vivo
prostate tissue model system identifies ING3 as an oncoprotein
2018
Dr Urszula McClurg
Dr Mahsa Azizyan
Dr Sirintra Nakjang
Dr Stuart McCracken
Professor Craig Robson
et al.
Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12
2018
Dr Urszula McClurg
Dr Mahsa Azizyan
Dr Sirintra Nakjang
Professor Craig Robson
The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival
2018
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...